Sign up Australia
Proactive Investors - Run By Investors For Investors

MGC Pharmaceuticals launches cannabidiol cream for psoriasis

The global market for psoriasis treatment was valued at US$7.8 billion in 2015.
MGC Pharmaceuticals launches cannabidiol cream for psoriasis
The cream helps reduce itching, flaking and dryness of skin

MGC Pharmaceuticals Ltd (ASX:MXC) has launched its first Derma Plus product -  Herbal Repair Cream containing cannabidiol (CBD) compounds, used for the daily relief of mild forms of psoriasis.

The Derma Plus range, comprising 3 products, completed successful clinical tests at a leading independent European dermatological clinic during H2 2017.

The psoriasis symptoms successfully treated through the independent tests include effective reduction of skin irritation, treatment of skin itchiness, flaking and severe dryness.

Two additional Derma Plus products for relief from acne and dermatitis conditions, the Herbal Balm and Herbal Replenish Cream, are also planned for launch during Q1 2018.

Psoriasis treatment is a multi-billion dollar market

According to the International Federation of Psoriasis Association, circa 5% people suffer from one or more forms of psoriasis, globally.

In the U.S. alone, the condition affects nearly 7.5 million people, which is roughly 2% of the population.

The global market for psoriasis treatment, which was valued at US$7.8 billion in 2015, is projected to expand at a compound annual growth rate (CAGR) of 5.1% to reach US$12.1 billion by 2024.

Successful independent European clinical testing

MGC’s product has been successfully clinically tested to confirm its efficacy in persons with psoriasis by Dr Rok Devjak, at a leading dermatological clinic in Slovenia.

Results from the clinical test program showed that the Herbal Repair Cream helps to significantly reduce itching, flaking and dryness as well as reduce the symptoms of dry skin for people with psoriasis.

The Herbal Repair Cream is now available for sale through MGC Derma’s website and other eCommerce platforms.

View full MXC profile View Profile

MGC Pharmaceuticals Timeline

Related Articles

1513583223_shutterstock_86097949.jpg
December 18 2017
VAL201 is a treatment for metastatic prostate cancer and other solid tumours
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
boy leaning against chain link fence
September 14 2017
We take a look back at the progress made by Summit in the five years since we first spoke to chief executive Glyn Edwards

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use